|
IL315833A
(en)
|
2010-08-02 |
2024-11-01 |
Regeneron Pharma |
Mice producing binding proteins containing VL regions
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
TWI635098B
(zh)
|
2013-02-01 |
2018-09-11 |
再生元醫藥公司 |
含嵌合恆定區之抗體
|
|
CA3078121A1
(en)
|
2013-09-13 |
2015-03-19 |
Beigene Switzerland Gmbh |
Anti-pd1 antibodies and their use as therapeutics and diagnostics
|
|
EA201691027A1
(ru)
|
2013-11-20 |
2016-12-30 |
Ридженерон Фармасьютикалз, Инк. |
Модуляторы aplnr и их применение
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
CN106255410B
(zh)
|
2014-03-21 |
2020-01-10 |
瑞泽恩制药公司 |
产生单结构域结合蛋白的非人动物
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
KR102130600B1
(ko)
|
2014-07-03 |
2020-07-08 |
베이진 엘티디 |
Pd-l1 항체와 이를 이용한 치료 및 진단
|
|
BR112017001385B1
(pt)
|
2014-07-22 |
2023-12-05 |
Cb Therapeutics, Inc. |
Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
|
|
ES2987034T3
(es)
|
2014-08-05 |
2024-11-13 |
Apollomics Inc |
Anticuerpos anti-PD-L1
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
AU2015317899A1
(en)
|
2014-09-16 |
2017-04-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-glucagon antibodies and uses thereof
|
|
EP3699198B1
(en)
*
|
2014-11-17 |
2025-03-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
|
RU2020122439A
(ru)
|
2014-11-24 |
2020-09-24 |
Регенерон Фармасьютикалз, Инк. |
Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
|
|
CN113603795A
(zh)
|
2014-12-05 |
2021-11-05 |
纪念斯隆-凯特琳癌症中心 |
靶向b-细胞成熟抗原的嵌合抗原受体及其用途
|
|
SMT202100221T1
(it)
|
2014-12-05 |
2021-07-12 |
Memorial Sloan Kettering Cancer Center |
Anticorpi bersaglianti l'antigene di maturazione delle cellule e metodi d'uso
|
|
CN109072199B
(zh)
|
2014-12-05 |
2022-10-28 |
纪念斯隆-凯特琳癌症中心 |
靶向Fc受体样5的嵌合抗原受体及其用途
|
|
CN107438622A
(zh)
|
2015-03-19 |
2017-12-05 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
|
DK3277725T3
(da)
|
2015-03-30 |
2021-01-11 |
Regeneron Pharma |
Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
|
|
CA2984249A1
(en)
|
2015-04-29 |
2016-11-03 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
|
EA039429B1
(ru)
*
|
2015-05-13 |
2022-01-26 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения опухолей с применением биспецифического антитела cd3xcd20
|
|
MY189159A
(en)
|
2015-07-06 |
2022-01-29 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
KR101712638B1
(ko)
*
|
2015-08-19 |
2017-03-07 |
한국과학기술연구원 |
Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제
|
|
TWI783914B
(zh)
|
2015-09-23 |
2022-11-21 |
美商再生元醫藥公司 |
最優化抗ｃｄ３雙特異性抗體及其用途
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
TWI824372B
(zh)
|
2015-10-12 |
2023-12-01 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
PH12018501177B1
(en)
|
2015-12-04 |
2024-01-24 |
Eureka Therapeutics Inc |
Antibodies targeting fc receptor-like 5 and methods of use
|
|
RS64588B1
(sr)
|
2015-12-22 |
2023-10-31 |
Regeneron Pharma |
Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera
|
|
EP3433281A1
(en)
|
2016-03-21 |
2019-01-30 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2017184831A1
(en)
*
|
2016-04-20 |
2017-10-26 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of an expression-enhancing locus
|
|
KR102906454B1
(ko)
*
|
2016-04-20 |
2026-01-02 |
리제너론 파마슈티칼스 인코포레이티드 |
발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
|
|
US11352446B2
(en)
|
2016-04-28 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
IL321475A
(en)
|
2016-05-06 |
2025-08-01 |
Medimmune Llc |
Bispecific binding proteins and their uses
|
|
TWI755395B
(zh)
|
2016-05-13 |
2022-02-21 |
美商再生元醫藥公司 |
抗-pd-1抗體與輻射治療癌症之組合
|
|
CN107474136B
(zh)
*
|
2016-06-08 |
2023-03-07 |
上海交通大学医学院 |
增强激动型抗体活性的抗体重链恒定区序列
|
|
EP3468990B1
(en)
|
2016-06-14 |
2024-03-27 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antibodies and uses thereof
|
|
CN109475536B
(zh)
|
2016-07-05 |
2022-05-27 |
百济神州有限公司 |
用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合
|
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
CN106191072A
(zh)
*
|
2016-08-04 |
2016-12-07 |
沈沭彤 |
重组人源嵌合GcFc基因片段及融合蛋白
|
|
ES2971881T3
(es)
|
2016-08-19 |
2024-06-10 |
Beigene Switzerland Gmbh |
Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer
|
|
IL265309B2
(en)
|
2016-09-23 |
2024-04-01 |
Regeneron Pharma |
Bispecific anti-muc16 antibodies and anti-muc16 antibodies for use in treating cancer
|
|
IL295509A
(en)
|
2016-09-23 |
2022-10-01 |
Regeneron Pharma |
Steap2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Compounds That Bind Steap2 and CD3, and Their Uses
|
|
SI3538554T1
(sl)
|
2016-11-08 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Proteini, ki vežejo antigen, ki antagonizirajo leptinski receptor
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
MX389083B
(es)
|
2016-12-01 |
2025-03-20 |
Regeneron Pharma |
Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet.
|
|
US11555038B2
(en)
|
2017-01-25 |
2023-01-17 |
Beigene, Ltd. |
Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
|
|
MX2019009565A
(es)
|
2017-02-10 |
2020-02-24 |
Regeneron Pharma |
Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet.
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
CN114989305A
(zh)
*
|
2017-03-31 |
2022-09-02 |
北京智仁美博生物科技有限公司 |
新型双特异性抗体及其用途
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
IL270267B2
(en)
|
2017-05-06 |
2024-06-01 |
Regeneron Pharma |
Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
|
|
JP2020522254A
(ja)
|
2017-05-31 |
2020-07-30 |
エルスター セラピューティクス， インコーポレイテッド |
骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
|
|
IL271193B2
(en)
|
2017-06-07 |
2025-01-01 |
Regeneron Pharma |
Preparations and methods for internalizing enzymes
|
|
US11597768B2
(en)
|
2017-06-26 |
2023-03-07 |
Beigene, Ltd. |
Immunotherapy for hepatocellular carcinoma
|
|
AU2018290856B2
(en)
|
2017-06-28 |
2025-06-26 |
Regeneron Pharmaceuticals, Inc. |
Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
|
|
US10730944B2
(en)
|
2017-07-24 |
2020-08-04 |
Regeneron Pharmaceuticals, Inc. |
Anti-CD8 antibodies and uses thereof
|
|
TWI865430B
(zh)
|
2017-07-24 |
2024-12-11 |
美商再生元醫藥公司 |
穩定化之抗體組合物及其製法
|
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
EP3688029A1
(en)
|
2017-09-29 |
2020-08-05 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
|
|
US11066475B2
(en)
|
2017-11-01 |
2021-07-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
|
|
WO2019108795A1
(en)
|
2017-11-29 |
2019-06-06 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
|
|
KR20200098528A
(ko)
|
2017-12-13 |
2020-08-20 |
리제너론 파아마슈티컬스, 인크. |
항-c5 항체 조합물 및 이의 용도
|
|
MX2020006508A
(es)
|
2017-12-18 |
2020-09-17 |
Regeneron Pharma |
Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas.
|
|
CN109971720B
(zh)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
靶向ErbB受体家族的嵌合抗原受体修饰T细胞及其用途
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
EP3514171A1
(en)
*
|
2018-01-18 |
2019-07-24 |
Molecular Cloning Laboratories (MCLAB) LLC |
Long-acting therapeutic fusion proteins
|
|
SG11202006379UA
(en)
|
2018-01-26 |
2020-07-29 |
Regeneron Pharma |
Human antibodies to influenza hemagglutinin
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
RS66546B1
(sr)
|
2018-03-24 |
2025-03-31 |
Regeneron Pharma |
Genetički modifikovani miševi ili pacovi za dobijanje terapeutskih antitela protiv peptid‑mhc kompleksa, postupci za njihovo dobijanje i upotrebe
|
|
US11608381B2
(en)
|
2018-04-06 |
2023-03-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treatment using a leptin receptor agonist antibody
|
|
AU2019262953B2
(en)
|
2018-04-30 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
|
|
JP7477462B2
(ja)
|
2018-05-17 |
2024-05-01 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｃｄ６３抗体、コンジュゲート、及び、それらの使用
|
|
JP7634993B2
(ja)
|
2018-06-19 |
2025-02-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
|
|
TWI890661B
(zh)
|
2018-06-21 |
2025-07-21 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
AU2019325565B2
(en)
|
2018-08-23 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Anti-Fc epsilon-R1 alpha (FceR1a) antibodies, bispecific antigen-binding molecules that bind FceR1a and CD3, and uses thereof
|
|
PL3844189T3
(pl)
|
2018-08-31 |
2025-03-31 |
Regeneron Pharmaceuticals, Inc. |
Strategia dawkowania, która łagodzi zespół uwalniania cytokin, dla przeciwciał dwuswoistych cd3/cd20
|
|
MY205168A
(en)
|
2018-10-23 |
2024-10-04 |
Regeneron Pharma |
Anti-npr1 antibodies and uses thereof
|
|
MA55134A
(fr)
|
2018-11-21 |
2021-09-29 |
Regeneron Pharma |
Anticorps anti-staphylococcus et leurs utilisations
|
|
MA66057B2
(fr)
|
2018-12-21 |
2025-09-30 |
Regeneron Pharmaceuticals, Inc |
Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci
|
|
MX2021008958A
(es)
|
2019-02-01 |
2021-11-04 |
Regeneron Pharma |
Proteínas de unión a antígeno del receptor gamma anti-il2.
|
|
CA3127696A1
(en)
|
2019-02-12 |
2020-08-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
|
CN114127111B
(zh)
|
2019-02-21 |
2024-09-10 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
CN114127113A
(zh)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
与钙网蛋白结合的多功能分子及其用途
|
|
JP7737306B2
(ja)
|
2019-02-21 |
2025-09-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
AU2020226904B2
(en)
|
2019-02-21 |
2025-05-01 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
WO2020198009A1
(en)
*
|
2019-03-22 |
2020-10-01 |
Regeneron Pharmaceuticals, Inc. |
EGFR x CD28 MULTISPECIFIC ANTIBODIES
|
|
EP3956664A1
(en)
*
|
2019-04-18 |
2022-02-23 |
Genentech, Inc. |
Antibody potency assay
|
|
TW202106708A
(zh)
|
2019-04-24 |
2021-02-16 |
美商銳進科斯生物股份有限公司 |
全人類轉譯後修飾之抗體治療劑
|
|
BR112021023335A2
(pt)
|
2019-06-11 |
2022-01-04 |
Regeneron Pharma |
Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
|
|
MX2021015270A
(es)
|
2019-06-21 |
2022-01-18 |
Regeneron Pharma |
Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb.
|
|
US20200399372A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
|
|
CN120842425A
(zh)
|
2019-08-08 |
2025-10-28 |
再生元制药公司 |
新型抗原结合分子形式
|
|
KR20220044821A
(ko)
|
2019-08-15 |
2022-04-11 |
리제너론 파아마슈티컬스, 인크. |
세포 표적화를 위한 다중특이적 항원-결합 분자 및 이의 용도
|
|
US11896682B2
(en)
|
2019-09-16 |
2024-02-13 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof
|
|
BR112022007923A2
(pt)
|
2019-10-28 |
2022-07-26 |
Regeneron Pharma |
Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza
|
|
AU2020379735A1
(en)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharmaceuticals, Inc. |
N-terminal SCFV multispecific binding molecules
|
|
US11919965B2
(en)
|
2019-12-06 |
2024-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
|
|
US12091440B2
(en)
|
2019-12-20 |
2024-09-17 |
Regeneron Pharmaceuticals, Inc. |
IL2 and peptide-MHC complex fusion proteins and methods of use thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
MX2022008494A
(es)
|
2020-01-08 |
2022-10-10 |
Regeneron Pharma |
Tratamiento de la fibrodisplasia osificante progresiva.
|
|
EP4103617A1
(en)
|
2020-02-11 |
2022-12-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvr1 antibodies and uses thereof
|
|
CN111411079B
(zh)
*
|
2020-03-27 |
2025-12-12 |
北京时合生物科技有限公司 |
细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用
|
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
AU2021268026A1
(en)
|
2020-05-08 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
VEGF traps and mini-traps and methods for treating ocular disorders and cancer
|
|
IL298007A
(en)
*
|
2020-05-12 |
2023-01-01 |
Regeneron Pharma |
Novel il10 agonists and methods of use thereof
|
|
AU2021283349A1
(en)
|
2020-06-03 |
2023-02-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
|
|
US11197910B1
(en)
*
|
2020-08-19 |
2021-12-14 |
Vitruviae LLC |
Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
|
|
EP4204458A4
(en)
|
2020-08-26 |
2024-10-09 |
Marengo Therapeutics, Inc. |
METHODS FOR DETECTION OF TRBC1 OR TRBC2
|
|
WO2022046920A2
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
US20250326861A1
(en)
|
2020-09-15 |
2025-10-23 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
KR20230069969A
(ko)
|
2020-09-15 |
2023-05-19 |
리제너론 파마슈티칼스 인코포레이티드 |
통증에 대한 lepr 아고니스트의 사용
|
|
US11905332B2
(en)
|
2020-09-18 |
2024-02-20 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
|
|
JP2023544164A
(ja)
|
2020-10-02 |
2023-10-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
サイトカイン放出症候群の低減を伴うがんを治療するための抗体の組合せ
|
|
WO2022087243A1
(en)
|
2020-10-22 |
2022-04-28 |
Regeneron Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies and methods of use thereof
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
JP2023547832A
(ja)
|
2020-10-28 |
2023-11-14 |
リジェネックスバイオ インコーポレイテッド |
眼の適応症に対するベクター化抗ＴＮＦ－α抗体
|
|
WO2022094255A2
(en)
|
2020-10-29 |
2022-05-05 |
Regenxbio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
AU2021369833A1
(en)
|
2020-10-29 |
2023-06-08 |
Regenxbio Inc. |
Vectorized tnf-alpha antagonists for ocular indications
|
|
IL303542A
(en)
|
2020-12-18 |
2023-08-01 |
Regeneron Pharma |
Immunoglobulin proteins that bind to NPR1 agonists
|
|
EP4271479A1
(en)
|
2020-12-29 |
2023-11-08 |
RegenxBio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
|
WO2022165171A1
(en)
|
2021-01-28 |
2022-08-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating cytokine release syndrome
|
|
GB2623199A
(en)
|
2021-04-08 |
2024-04-10 |
Marengo Therapeutics Inc |
Multifunctional molecules binding to TCR and uses thereof
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
WO2022235628A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
|
CN117730099A
(zh)
|
2021-05-11 |
2024-03-19 |
瑞泽恩制药公司 |
抗tmprss6抗体及其用途
|
|
CA3226924A1
(en)
|
2021-07-19 |
2023-01-26 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
KR20240046251A
(ko)
|
2021-08-16 |
2024-04-08 |
리제너론 파아마슈티컬스, 인크. |
신규 il27 수용체 효능제 및 그의 사용 방법
|
|
WO2023081434A2
(en)
|
2021-11-07 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
|
WO2023086812A1
(en)
|
2021-11-11 |
2023-05-19 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
KR20240103062A
(ko)
|
2021-11-24 |
2024-07-03 |
리제너론 파아마슈티컬스, 인크. |
이중 특이적 항CD3 x MUC16 항체 및 항CTLA-4 항체로 암을 치료하는 방법
|
|
MX2024006812A
(es)
|
2021-12-06 |
2024-08-19 |
Regeneron Pharma |
Anticuerpos antagonistas anti-npr1 y metodos de uso de los mismos.
|
|
IL313864A
(en)
|
2022-01-07 |
2024-08-01 |
Regeneron Pharma |
Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1
|
|
TW202400228A
(zh)
|
2022-02-25 |
2024-01-01 |
美商再生元醫藥公司 |
減輕細胞激素釋放症候群的給藥方案
|
|
KR20240168484A
(ko)
|
2022-03-03 |
2024-11-29 |
예일 유니버시티 |
인간화 3e10 항체, 변이체, 및 항원 결합 단편
|
|
AU2023236126A1
(en)
|
2022-03-17 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
|
KR20250004700A
(ko)
|
2022-04-11 |
2025-01-08 |
리제너론 파마슈티칼스 인코포레이티드 |
보편적 종양 세포 사멸을 위한 조성물 및 방법
|
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
EP4518973A1
(en)
|
2022-05-03 |
2025-03-12 |
RegenxBio Inc. |
Vectorized anti-tnf-alpha inhibitors for ocular indications
|
|
IL316892A
(en)
|
2022-05-11 |
2025-01-01 |
Regeneron Pharma |
Multispecific proprotein binding molecules and their uses
|
|
CN119421723A
(zh)
|
2022-05-16 |
2025-02-11 |
瑞泽恩制药公司 |
用双特异性抗PSMA x抗CD3抗体单独或与抗PD-1抗体组合治疗转移性去势抵抗性前列腺癌的方法
|
|
KR20250011926A
(ko)
|
2022-05-18 |
2025-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
Cd38 및 4-1bb에 결합하는 다중특이적 항원 결합 분자, 및 이의 용도
|
|
US20230382969A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
EP4536690A1
(en)
|
2022-06-04 |
2025-04-16 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
|
CA3261203A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS OF ADMINISTRATION MEDIATED BY THE TRANSFERRIN RECEPTOR (TFR) TO THE BRAIN AND MUSCLE
|
|
EP4561598A1
(en)
|
2022-07-29 |
2025-06-04 |
Regeneron Pharmaceuticals, Inc. |
Viral particles retargeted to transferrin receptor 1
|
|
CN120265655A
(zh)
|
2022-07-29 |
2025-07-04 |
瑞泽恩制药公司 |
抗tfr：有效载荷融合物及其使用方法
|
|
KR20250043547A
(ko)
|
2022-08-02 |
2025-03-28 |
리제너론 파아마슈티컬스, 인크. |
이중특이적 항-PSMA x 항-CD28 항체를 항-PD-1 항체와 병용으로 사용하여 전이성 거세 저항성 전립선암을 치료하는 방법
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
WO2024040247A1
(en)
|
2022-08-18 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
|
IL319877A
(en)
|
2022-10-03 |
2025-05-01 |
Regeneron Pharma |
Methods for treating cancer with bispecific EGFR X CD28 antibodies alone or in combination with anti-PD-1 antibodies
|
|
IL319818A
(en)
|
2022-10-10 |
2025-05-01 |
Regeneron Pharma |
Methods for reducing alloantibody levels in patients requiring solid organ transplantation
|
|
WO2024092038A2
(en)
|
2022-10-25 |
2024-05-02 |
Ablexis, Llc |
Anti-cd3 antibodies
|
|
EP4608865A1
(en)
|
2022-10-27 |
2025-09-03 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
JP2025538220A
(ja)
|
2022-11-14 |
2025-11-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法
|
|
KR20250120451A
(ko)
|
2022-11-14 |
2025-08-08 |
리제너론 파마슈티칼스 인코포레이티드 |
항-fgfr3 항체 및 항원 결합 단편 및 이의 사용 방법
|
|
WO2024107731A2
(en)
|
2022-11-14 |
2024-05-23 |
Ablexis, Llc |
Anti-pd-l1 antibodies
|
|
EP4634220A2
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
EP4638502A2
(en)
|
2022-12-21 |
2025-10-29 |
Genzyme Corporation |
Anti-pd-1×4-1bb binding proteins
|
|
EP4638729A1
(en)
|
2022-12-23 |
2025-10-29 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
KR20250148746A
(ko)
|
2023-01-13 |
2025-10-14 |
리제너론 파아마슈티컬스, 인크. |
Fgfr3 결합 분자 및 그의 사용 방법
|
|
AU2024207005A1
(en)
|
2023-01-13 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
IL322397A
(en)
|
2023-02-13 |
2025-09-01 |
Regeneron Pharma |
Treating muscle-related disorders with anti-human CACNG1 antibodies
|
|
AR131856A1
(es)
|
2023-02-16 |
2025-05-07 |
Sanofi Sa |
Proteínas de unión a cd40
|
|
US20240299601A1
(en)
|
2023-02-17 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
AU2024223918A1
(en)
|
2023-02-17 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
|
IL322940A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multivalent anti-spike protein binding molecules and their uses
|
|
US20240287186A1
(en)
|
2023-02-28 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
T cell activators and methods of use thereof
|
|
IL322941A
(en)
|
2023-02-28 |
2025-10-01 |
Regeneron Pharma |
Multivalent anti-spike protein binding molecules and their uses
|
|
AU2024265507A1
(en)
|
2023-05-02 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
|
|
AU2024269008A1
(en)
|
2023-05-10 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
US20240376229A1
(en)
|
2023-05-12 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
WO2024258785A1
(en)
|
2023-06-11 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
AU2024304472A1
(en)
|
2023-06-16 |
2026-01-08 |
Regeneron Pharmaceuticals, Inc. |
Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
|
|
AU2023454911A1
(en)
|
2023-07-10 |
2026-01-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-human cacng1 antibody-drug conjugates and uses thereof
|
|
US20250043017A1
(en)
|
2023-07-10 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
|
|
US20250043002A1
(en)
|
2023-07-10 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
BISPECIFIC PD-L1xCD28 ANTIBODIES AND METHODS OF USE THEREOF
|
|
AU2024291721A1
(en)
|
2023-07-19 |
2026-01-22 |
Regeneron Pharmaceuticals, Inc. |
ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF
|
|
AU2024317483A1
(en)
|
2023-07-28 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
AU2024317508A1
(en)
|
2023-07-28 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr: acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
WO2025030041A1
(en)
|
2023-08-02 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025030044A1
(en)
|
2023-08-02 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025049591A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-cxcr4 antibodies and uses thereof
|
|
WO2025080540A1
(en)
|
2023-10-09 |
2025-04-17 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of a taaxcd3 bispecific antibody and a targeted immunocytokine
|
|
US20250154487A1
(en)
|
2023-11-10 |
2025-05-15 |
Regeneron Pharmaceuticals, Inc. |
Engineered alpha klotho polypeptides and uses thereof
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
TW202539732A
(zh)
|
2023-11-29 |
2025-10-16 |
美商再生元醫藥公司 |
以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025128652A1
(en)
|
2023-12-12 |
2025-06-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating endometrial cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
WO2025160340A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025171124A1
(en)
|
2024-02-07 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prostate cancer with bispecific anti-psma x anti-cd3 antibodies and bispecific anti-psma x anti-cd28 antibodies
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025184603A2
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
WO2025199278A2
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Masked multispecific antigen-binding molecules with cleavable linkers
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
WO2025217230A1
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
|
WO2025240287A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025244973A1
(en)
|
2024-05-20 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies
|
|
US20250361309A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025255508A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Engineered alpha klotho polypeptides and uses thereof
|
|
WO2025255480A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
WO2025259718A2
(en)
|
2024-06-11 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
|
US20260000758A1
(en)
|
2024-06-28 |
2026-01-01 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026015612A1
(en)
|
2024-07-10 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating smarcb1-deficient cancers
|
|
US20260014252A1
(en)
|
2024-07-11 |
2026-01-15 |
Regeneron Pharmaceuticals, Inc. |
GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof
|
|
WO2026025058A1
(en)
|
2024-07-25 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Aav viral particles retargeted to egfr-expressing cancer cells
|